Hims & Hers Health (HIMS) Preferred Stock Liabilities (2019 - 2020)
Hims & Hers Health (HIMS) reported Preferred Stock Liabilities of $250.0 million for Q4 2020, up 5454.71% on a YoY basis from $4.5 million in Q1 2020, and up 9.57% sequentially from $228.1 million in Q2 2020.
Hims & Hers Health (HIMS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Hims & Hers Health (HIMS) has 2 years of Preferred Stock Liabilities data on file, last reported at $250.0 million in Q4 2020.
- For the quarter ending Q4 2020, Preferred Stock Liabilities rose 5454.71% year-over-year to $250.0 million; the trailing twelve-month figure through Dec 2020 stood at $250.0 million (up 5454.71% YoY), and the FY2020 full-year result was $250.0 million, up 5454.71% from the prior year.
- Preferred Stock Liabilities rose to $250.0 million in Q4 2020, from $228.1 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $250.0 million in Q4 2020 to a low of $4.5 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 249.96 Mn |
| Jun 30, 2020 | 228.13 Mn |
| Mar 31, 2020 | 218.25 Mn |
| Dec 31, 2019 | 4.50 Mn |